Goldman Sachs initiated coverage of Royalty Pharma (RPRX) with a Buy rating and $42 price target which represents 20% upside. The company offers investors a way to gain exposure to a portfolio of biopharma royalty streams without incurring biotech’s “volatility and binary risks,” the analyst tells investors in a research note. The firm believes Royalty is in the early stages of a portfolio expansion that is underappreciated in the context of a large, growing total addressable market for royalty funding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma appoints Ted Love as lead independent director
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/17/2025
- Royalty Pharma Completes $2 Billion Senior Notes Offering
- Royalty Pharma: Strong Performance and Promising Outlook Justify Buy Rating
- Royalty Pharma ‘on track’ to deliver portfolio receipts of $4.7B by 2030